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Abstract 
Background: Influenza virus pandemics vary dramatically in their severity and mortality. Thus, it is very important to 
identify populations with high risks of developing severe illness to reduce mortality in future pandemics. The purpose 
was to determine the mortality‑associated risk factors in hospitalized Mexican patients infected with influenza A/
H1N1.
Results: The risk factors associated with mortality were: male sex [odds ratio (OR) = 5.25, confidence interval 
(CI) = 1.22–28.95], medical attention delayed >3 days (OR = 9.9, CI = 1.51–64.52), anti‑flu therapy delayed >3 days 
(OR = 10.0, CI = 1.07–93.43), admission to intensive care unit (ICU) (OR = 9.9, CI = 1.51–64.52) and creatinine levels 
>1.0 mg/dL when admitted to hospital (OR = 11.2, CI = 1.05–120.32). After adjusting for the effects of potentially con‑
founding variables in a logistic regression model, delayed medical attention (OR = 13.91, CI = 1.09–41.42, p = 0.044) 
and ICU hospitalization (OR = 11.02, CI = 1.59–76.25, p = 0.015) were the only predictors of mortality.
Conclusion: Early medical attention is essential for reducing the mortality risk in patients with influenza A/H1N1, 
while a requirement for ICU management increases the risk.
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Background
Pandemic influenza A (H1N1) virus infection varies in 
its severity. However, little is known about the infectivity 
and transmissibility of the 2009 H1N1 pandemic influ-
enza (pH1N1) virus outside Mexico. Pneumonia was 
reported to be the major cause of hospitalization and 
death in confirmed cases of H1N1 [1]. Delayed antiviral 
treatment, severe hypoxemia and multisystem organ fail-
ure have been reported to be negative prognostic factors 
in critically ill patients with influenza, while early diagno-
sis, assessment of high risk and the analysis of epidemic 
pneumonia may be useful for assessing the risk of this 
virus and the possibility of its control [2].
Active surveillance of severe pneumonia was initiated 
at the Instituto Mexicano del Seguro Social (IMSS) after 
the first epidemiological alert during April 2009 when 
influenza was not expected to reach epidemic levels. 
In total, 117,626 influenza-like illness (ILI) cases were 
reported by IMSS between April and December 2009, of 
which 36,044 were laboratory-tested (30.6 %) and 27,440 
(23.3 %) were confirmed as pandemic influenza A/H1N1. 
A total of 1370 ILI deaths (3.6 per 100,000) were reported 
to the surveillance system, of which 585 (1.5 per 100,000) 
were confirmed as A/H1N1 virus infections [3–6]. Of 
6945 cases reported by IMSS as novel A/H1N1 infec-
tions, <1 % died and 7 % were hospitalized [3–6]. Another 
study was conducted in six hospitals between March and 
June during 2009, which showed that 58/899 hospitalized 
patients developed critical illness [4, 5].
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The clinical, virological and immunological parameters 
associated with the clinical severity of this virus have 
been explored in recent studies [6, 7]. The influenza virus 
is primarily a respiratory pathogen but the clinical mani-
festations in severe infections are not always restricted 
to the respiratory tract and they more closely resemble 
those of a systemic infection. In some countries, 10–30 % 
of patients with H1N1 infection required admission to 
intensive care units (ICUs) [8].
Most previous studies of the 2009 H1N1 outbreak 
in Mexico focused on critically ill patients [9–11]. The 
H1N1 virus pandemic caused significant morbidity and 
mortality in certain demographic groups, such as the 
very old, pregnant women and obese patients [12].
The aim of this study was to identify clinically useful 
predictors of mortality and the disease severity of H1N1 
pneumonia.
Methods
The study was conducted in accordance with the ethics 
principles of the Declaration of Helsinki (Helsinki, Fin-
land). Written informed consent was obtained from each 
participant. The study was approved by the Local Com-
mittee for Health Research 35021 Hospital de Infectolo-
gia “La Raza” National Medical Center, with corporate 
registration number R-2010-35021-5.
Surveillance and data collection
ILI was defined as a combination of cough, headache and 
fever (except in persons aged over 65 years) with one or 
more of the following symptoms: sore throat, rhinor-
rhoea, arthralgia, myalgia, prostration, thoracic pain, 
abdominal pain, nasal congestion, diarrhoea and irritabil-
ity [3].
Participants
A case–control study was designed to investigate the 
factors associated with unfavourable prognosis (mor-
tality) among in-patients with documented influenza 
A/H1N1 infection. The participants attended the Hos-
pital de Infectología, National Medical Center “La 
Raza”, in Mexico City between April and November 
2009. The cases were patients who died during hospi-
talization whereas the controls were discharged after 
their improvement. The patients included were aged 
>18  years and were confirmed as A/H1N1-positive by 
reverse transcriptase PCR. We defined the patients with 
severe disease as those who died with confirmed influ-
enza A/H1N1 infection, or those who were admitted to 
the ICU and/or were intubated for severe respiratory 
symptoms associated with influenza A/H1N1. A total 
of 33 patients met the inclusion criteria in this medical 
centre.
Sample collection
We obtained ILI surveillance data and the results of 
laboratory-tested samples for all individuals who sought 
hospital medical care for ILI symptoms between April 
and November during 2009. Nasopharyngeal swabs 
and/or bronchoalveolar lavage samples were sent to the 
diagnostic reference laboratory with standardized ques-
tionnaires, including demographic and epidemiological/
clinical information. The swab samples and specimens 
were homogenized in virus transport medium and kept 
on ice before diagnosis. The data collected included, gen-
eral attributes, medical history, symptoms, records of 
respiratory evolution and routine laboratory tests. Each 
suspected case of ILI was laboratory-confirmed as nega-
tive or positive for pandemic influenza A/H1N1. The 
diagnosis of influenza was invariably provided within 
8–24 h after the receipt of the sample. Swabs were tested 
for A/H1N1 influenza virus by real-time PCR at the 
Instituto de Diagnóstico y Referencia Epidemiológica 
(InDRE), after which point samples were analysed by “La 
Raza”, which is an IMSS laboratory certified by InDRE [3]. 
To perform a rapid diagnosis, specific primers and probes 
were used to detect influenza A/H1N1. The quantita-
tive real-time PCR primers were based on the conserved 
matrix protein gene, according to World Health Organi-
zation (WHO) recommendations. Further analyses and 
confirmation were carried out according to Center for 
Disease Control and Prevention and WHO guidelines.
Statistical analysis
The results were compared using the Mann–Whitney 
U-test and p  <  0.05 was considered sufficient to merit 
investigation as a factor associated with unfavour-
able prognosis (mortality) among in-patients with docu-
mented influenza A/H1N1 infection.
A logistic regression model was used to analyse the 
associations between the variables of interest. The results 
were expressed as odds ratios (ORs), and the 95 % confi-
dence intervals (CIs) were calculated for each predictive 
factor and mortality risk. The statistical analyses were 




In total, 33 patients with influenza A/H1N1 infec-
tion were confirmed by quantitative real-time PCR, of 
whom 11 were cases (patients who died) and 22 were 
controls (patients who were discharged after improve-
ment). Twelve of the patients (38  %) were men: seven 
(63  %) in the case group and five (25  %) in the control 
group. The medians of the subject age inter-quartile 
ranges (IQRs) were 29 years (IQR = 25–46) and 34 years 
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(IQR  =  22–44), respectively (p  =  0.685). Ten (90  %) 
cases and four (13  %) controls were hospitalized in the 
ICU (p  <  0.001). The cases experienced first medical 
visit delays of 3 days (IQR = 2–7) vs 1 day (IQR = 1–3), 
(p = 0.043) and oseltamivir treatment initiation delays of 
8 days (IQR = 6–10) vs 3 days (IQR = 2–7) (p = 0.038) 
(Table 1).
Risk factors associated with mortality
The risk factors associated with mortality were: male 
sex (OR  =  5.25, CI  =  1.22–28.95), ICU hospitalization 
(OR = 9.9, CI = 1.51–64.52), medical attention delayed 
>3 days (OR = 6.41, CI = 1.18–34.61), initiation of anti-
flu therapy (oseltamivir) delayed >3  days (OR  =  10.0, 
CI  =  1.07–93.43) and serum creatinine >1.0  mg/dL 
(OR = 11.2, CI = 1.05–120.32, p = 0.004) (Table 2). After 
adjusting for the effects of potentially confounding varia-
bles in a logistic regression model, we found that delayed 
medical attention (OR = 11.02, p = 0.015) and ICU hos-
pitalization (OR = 13.91, p = 0.044) were the only pre-
dictors of mortality (Table 3).
Discussion
During early April 2009, medical care units were alerted 
that the number of seasonal influenza cases had not 
decreased to expected levels and it was later confirmed 
that a novel influenza A/H1N1 virus caused the out-
break. The baseline estimate of the disease outbreak was 
that approximately 375,000 Mexicans had novel H1N1 
influenza infections with onset of symptoms by approxi-
mately 30 April, 2009 [13]. The increasing levels of hospi-
talized patients led to the design of a case–control study 
of hospitalized patients at the Hospital de Infectología, 
National Medical Center “La Raza”. This study elucidated 
the risk factors associated with influenza A/H1N1 mor-
tality. We found that delayed medical attention and ICU 
hospitalization were predictive factors associated with 
mortality in our population.
Most of the cases who died required ICU admis-
sion because of the disease severity. Similar data were 
reported in four previous studies. Patients with influ-
enza H1N1 were evaluated by Dominguez Cherit et  al. 
[14] in Mexico and by Kumar et  al. [15] in Canada. In 
Mexico, Echeverría-Zuno et al. and Louie et al. reported 
that all of the patients who died were admitted to ICU 
services. However, the patients differed with respect 
to the need for endotracheal intubation because there 
was no need for this procedure in Canada whereas 2/24 
patients required intubation in Mexico [16, 17]. One of 
our patients died and was not ICU hospitalized because 
the patient arrived at our hospital in a very bad condition 
and died in the emergency room.
Of the 11 cases evaluated, seven were male. A recent 
study in Canada showed that of 29 deaths, eight were 
men (27.6 %) and 21 women (72.4 %), although most stud-
ies state that male sex is a risk factor for acquiring influ-
enza A/H1N1 infection [15, 18]. A significant result was 
obtained for elevated serum creatinine (only in patients 
with confirmed H1N1) but it was not a predictive factor 
for mortality. Elevated serum creatinine was detected in 
11 cases and it was statistically significant [14, 18, 19].
The appropriate and timely use of oseltamivir to treat 
early influenza symptoms reduces the complications of 
the disease and the risk of mortality. Similar results have 
been reported in China, Mexico, Canada and the United 
States where the use of oseltamivir 48 h after the onset of 
symptoms reduces the risk of mortality, especially in preg-
nant women. This situation is acknowledged by the WHO 
Table 1 Baseline characteristics of patients with H1N1 infections
The data are expressed as percentages (%) or averages. p value according to Student’s t‑test, χ2 test or Fisher’s exact test. Median (IQR = 25–75)
IQR inter‑quartile range
* p < 0.05
a Type 2 diabetes, hypertension, asthma or HIV infection
Characteristics Cases n = 11 (%) Controls n = 22 (%) p value
Male 7 (63.6) 5 (22.7) 0.035*
Age 29 (IQR = 25–46) 34 (IQR = 22–44) 0.685
Lack of flu vaccination in previous year 11 (100) 15 (78.9) 0.674
Smoker 5 (45.5) 10 (45.5) 0.999
Overweight or obese 7 (63.6) 13 (59.1) 0.604
Chronic disease diagnosisa 5 (45.5) 4 (18.2) 0.097
First medical attention after onset of flu symptoms (days) 3 (IQR = 2–7) 1 (IQR = 1–3) 0.043*
Treatment initiation with oseltamivir after onset of flu symptoms (days) 8 (IQR = 6–10) 3 (IQR = 2–7) 0.038*
Intensive care unit hospitalization 10 (90.9) 3 (13.6) 0.001*
Received oseltamivir 10 (90.9) 20 (90.1) 0.999
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guidelines, which indicate that early initiation of oseltami-
vir for suspected influenza cases in pregnant women 
decreases the mortality risk whereas delayed medical 
attention increases the mortality rate [16–21]. The ben-
eficial early therapy with oseltamivir could be not useful 
in resistant virus like described in another studies and the 
intravenous medicaments have been used in patients with 
seasonal influenza and against Influenza A/H1N1 there 
are just in vitro beneficial results, randomized controlled 
trials there are not still made however [21].
This pandemic virus, suggest that we have to be pre-
pared against agents of emerging infectious diseases, in 
future pandemics, we have to act faster to prevent dissem-
ination. The influenza virus is highly unpredictable, and 
we should be ready for another pandemia. The challenges 
in successful vaccination against influenza lie in their vari-
able efficacy in different age populations, the antigenic 
variability of the circulating virus, and the production and 
manufacturing limitations to ensure safe, timely, and ade-
quate supply of vaccine. Future improvement will require 
novel approaches to both vaccine formulation and manu-
facturing processes. The actually studies to find a univer-
sal vaccine targeting all influenza virus with the expressed 
HA antigens are still under investigation, but until then 
we have to be prepared just with the antiviral weapons 
that by now we have and to our patients a early therapy 
offer to fast as possible [22].
The sample size was a limiting factor. The study was 
initiated during the second outbreak of the epidemic and 
there were a lower number of cases, which affected the 
number of patients available for collecting data, for that, 
this results should be taken carefully. In addition, most 
of the referred patients had already initiated antiviral 
therapy. However, the data were collected directly from 
the patients or using a questionnaire, and we followed the 
course of each patient until their death or improvement, 
using confirmatory tests and/or clinical checks.
Conclusions
In conclusion, the early detection of the signs and symp-
toms of this disease, immediate medical attention, antivi-
ral therapy and respiratory therapy slow the progression 
of influenza A/H1N1 and reduce the risk of mortality. 
The patients with a requirement for ICU management 
have an increased risk of mortality.
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Table 2 Risk factors associated with  mortality in  patients 
with influenza A/H1N1 based on a bivariate analysis
OR odds ratio, CI confidence interval
* Significant difference at p < 0.05
Risk factor Bivariate analysis
OR (95 % CI) p value
Male 5.25 (1.22–28.95) 0.004*
Lack of flu vaccination in previous year 11.12 (0.57–215.3) 0.057
Recent or past smoker 0.88 (0.18–4.38) 0.885
Overweight or obese 0.62 (0.09–3.91) 0.609
Chronic disease diagnosis† 3.12 (0.62–15.79) 0.160
Intensive care unit hospitalization 9.9 (1.51–64.52) <0.001*
Medical received attention after >3 days 6.41 (1.18–34.61) 0.018*
Anti‑flu treatment after >3 days 10.0 (1.07–93.43) 0.039*
Serum creatinine >1.0 mg/dL 11.2 (1.05–120.32) 0.004*
Table 3 Risk factors associated with  mortality in  patients 
with influenza A/H1N1 based on a multivariate analysis
OR odds ratio, CI confidence interval
* Significant difference at p < 0.05
Risk factor Multivariate analysis
OR (95 % CI) p value
First medical attention received after >3 days 11.02 (1.59–76.25) 0.015*
Male 2.73 (0.52–14.28) 0.233
Age 1.02 (0.95–1.01) 0.549
Recent or past smoker 1.19 (0.16–8.92) 0.867
Chronic disease diagnosis 4.91 (0.58–41.42) 0.144
Intensive care unit hospitalization 13.91 (1.09–41.42) 0.044*
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